September 16, 2022
Hepatologist Naim Alkhouri and Endocrinologist Scott Isaacs join Ken Cusi and Roger Green to discuss drug choices prescribers can make TODAY for patients with Type 2 Diabetes Mellitus and obesity that have positive impact on Fatty Liver disease.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
Surfers Roger Green, Jörn Schattenberg and Louise Campbell embark on their first exclusive discussion together in a while without any guest panelists. After several weeks of attending and reviewing conferences, the trio take the opportunity to talk about what the next year holds for the NAFLD-metabolic disease link.
In this conversation From Inside the Vault, NAIL-NIT co-leads Stephen Harrison and Mazen Noureddin and retrospective analysis co-leads Naim Alkhouri and Jörn Schattenberg join Louise Campbell and Roger Green to discuss designs and plans for NAIL-NIT retrospective analysis.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this final conversation, the group explores the rest of the Day Two program, focusing on the development of an NIT diagnostic pathway. Finally, each offers their closing remarks on being a part of the 8th Paris NASH Meeting and what the future looks like in this space.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses presentations on adaptive trial strategies, trial recruitment and reducing screen fail rates, and the impact of educating patients on better self-care.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group discusses the opening and closing sessions, data collection and the rate of growth for cirrhosis, and Fatty Liver in the metabolic context.
In a review of Paris NASH 2022, Surfers Roger Green, Louise Campbell, and Jörn Schattenberg are joined by patient advocate, Jeff McIntyre. In this conversation, the group shares one particularly striking takeaway from the meeting.
The importance of integrating the NAFLD and NASH field within a wider scope of metabolic health was emphasized at the 8th Paris NASH Meeting. Last week, Surfers Roger Green, Louise Campbell and Jörn Schattenberg were in attendance alongside patient advocate and episode guest, Jeff McIntyre.
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among
